AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12107605 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg BDP as four inhalations from 50 microg/actuation P&B
Number of subjects: 18
Study 12107605 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg BDP as four inhalations from 50 microg/actuation AH
Number of subjects: 18
Study 12107605 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg BDP as four inhalations from 100 microg/actuation AH
Number of subjects: 18
Study 12107605 — intervention group
Group type: COMPARATOR
Intervention: P&B inhaler
Number of subjects: 18
Study 12107605 — intervention group
Group type: COMPARATOR
Intervention: AH inhaler
Number of subjects: 18
Study 10443601 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg intrathecal clonidine
Number of subjects: 36
Study 10443601 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg intrathecal clonidine
Number of subjects: 36
Study 10443601 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg intrathecal clonidine
Number of subjects: 36
Study 7494722 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured treatment and teaching program for non-insulin-treated type II diabetic patients
Number of subjects: 0
Study 1580072 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-medication with antidiarrhoeal agents, analgesics/antipyretics, antibiotics, and oral contraceptives
Number of subjects: 193
Study 1580072 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-medication with pyrimethamine/sulfadoxine
Number of subjects: 193
Study 1580072 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-medication with mefloquine
Number of subjects: 193
Study 6716222 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium given as a bolus
Number of subjects: 27
Study 6716222 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium given as a drip
Number of subjects: 27
Study 6716222 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 27
Study 30789417 — intervention group
Group type: EXPERIMENTAL
Intervention: FOB-Gold
Number of subjects: 42179
Study 30789417 — intervention group
Group type: COMPARATOR
Intervention: OC-Sensor
Number of subjects: 42179
Study 28913825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nursing and medical approach
Number of subjects: 200
Study 28913825 — intervention group
Group type: COMPARATOR
Intervention: Medical follow-up only (control group)
Number of subjects: 200
Study 27225217 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian Heart Lifestyle Intervention
Number of subjects: 63
Study 27225217 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring with pedometers
Number of subjects: 63
Study 27225217 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater family involvement and women-only exercise classes
Number of subjects: 63
Study 27225217 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 63
Study 27225217 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based delivery and cultural adaptation
Number of subjects: 63
Study 24498853 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg orally
Number of subjects: 51
Study 22875231 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking after meals
Number of subjects: 24
Study 22875231 — intervention group
Group type: COMPARATOR
Intervention: Inactivity after meals
Number of subjects: 24
Study 20345024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique-pulling maneuver
Number of subjects: 65
Study 20345024 — intervention group
Group type: COMPARATOR
Intervention: Lumbar traction therapy
Number of subjects: 65
Study 17684661 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone for 60 days
Number of subjects: 85
Study 17684661 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 85
Study 16236737 — intervention group
Group type: EXPERIMENTAL
Intervention: One year of trastuzumab treatment
Number of subjects: 5077
Study 16236737 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 5077
Study 12198006 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg, elemental form as acetate, twice daily for 6 days)
Number of subjects: 85
Study 12198006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 12198006 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 85
Study 10192202 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal elastase-1 determination
Number of subjects: 28
Study 10192202 — intervention group
Group type: COMPARATOR
Intervention: Secretin-CCK test
Number of subjects: 28
Study 10192202 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal fat excretion
Number of subjects: 28
Study 8845088 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg once daily)
Number of subjects: 62
Study 8845088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 2127690 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy (CAF followed by PH)
Number of subjects: 301
Study 2127690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (CAF/PH)
Number of subjects: 301
Study 2127690 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (CAF greater than PH and CAF/PH)
Number of subjects: 301
Study 30856 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 22
Study 30856 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 31536746 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen dressing material
Number of subjects: 30
Study 31536746 — intervention group
Group type: COMPARATOR
Intervention: Foam dressing alone (control group)
Number of subjects: 30
Study 27754808 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg) daily for 1 to 6 menstrual cycles
Number of subjects: 1214
Study 27754808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1214
Study 25466493 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit Weight Training (CWT)
Number of subjects: 59
Study 25466493 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Number of subjects: 59
Study 25466493 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 59
Study 23398222 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment in addition to treatment-as-usual
Number of subjects: 78
Study 21117970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 625
Study 21117970 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg
Number of subjects: 625
Study 21117970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus Fenofibrate 160 mg
Number of subjects: 625
Study 21117970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study 19260251 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 grams of capsicum
Number of subjects: 12
Study 19260251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16717336 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine (group P)
Number of subjects: 40
Study 16717336 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine derived from 2% lidocaine diluted with saline (group D)
Number of subjects: 40
Study 15549367 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing on a treadmill until maximal oxygen consumption was achieved.
Number of subjects: 41
Study 15549367 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting systolic blood pressure difference greater than 2.67 kPa (20 mmHg).
Number of subjects: 41
Study 15549367 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing.
Number of subjects: 41
Study 11585001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium
Number of subjects: 0
Study 9218745 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high-carbohydrate diet (intensive individual counselling to reduce total dietary fat to 15% of calories)
Number of subjects: 220
Study 9218745 — intervention group
Group type: COMPARATOR
Intervention: Control group (general advice about diet without counselling to change fat intake)
Number of subjects: 220
Study 8483989 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (40 mg twice daily)
Number of subjects: 37
Study 8483989 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy living (diet and exercise)
Number of subjects: 37
Study 8483989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 3318424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg at bedtime
Number of subjects: 37
Study 3318424 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 250 mg twice daily
Number of subjects: 37
Study 31167195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal surgery for SB
Number of subjects: 20
Study 29617196 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisements for healthy foods from perceivably healthy restaurant brands
Number of subjects: 0
Study 29617196 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand commitment and health consciousness
Number of subjects: 0
Study 27008432 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Assisted Learning (PAL)
Number of subjects: 50
Study 27008432 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PAL)
Number of subjects: 50
Study 25652686 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 57
Study 24358141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 448
Study 24358141 — intervention group
Group type: COMPARATOR
Intervention: Dynamic compression plate (DCP)
Number of subjects: 448
Study 20433766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (special developed carton style nutrition education handbook)
Number of subjects: 9750
Study 20433766 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (Happy 10 program)
Number of subjects: 9750
Study 20433766 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention strategy
Number of subjects: 9750
Study 20433766 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education only
Number of subjects: 9750
Study 20433766 — intervention group
Group type: COMPARATOR
Intervention: Physical activity only
Number of subjects: 9750
Study 18657828 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula (PF)
Number of subjects: 49
Study 18657828 — intervention group
Group type: COMPARATOR
Intervention: Term formula (TF)
Number of subjects: 49
Study 16316811 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg two to three times per day)
Number of subjects: 116
Study 12904324 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid (PUFA) diet (fish oil capsules containing 3.2 g eicosapentaenoic acid and 2.2 g docohexaenoic acid)
Number of subjects: 20
Study 12904324 — intervention group
Group type: COMPARATOR
Intervention: Placebo diet (olive oil capsules)
Number of subjects: 20
Study 12904324 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 20
Study 12904324 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA diet
Number of subjects: 20
Study 10370739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung resection surgery
Number of subjects: 36
Study 10370739 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy for other reasons (Control)
Number of subjects: 36
Study 8900981 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercise (ITE)
Number of subjects: 19
Study 8900981 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercise (IKE)
Number of subjects: 19
Study 8900981 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NOE)
Number of subjects: 19
Study 2049249 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 5 mg kg‐1
Number of subjects: 6
Study 2049249 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 10 mg kg‐1
Number of subjects: 6
Study 2049249 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine 15 mg kg‐1
Number of subjects: 6
Study 6836710 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone infusion
Number of subjects: 6
Study 6836710 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study 31062046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulimorelin
Number of subjects: 120
Study 31062046 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 120
Study 28654669 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium chloride (248 mg of elemental magnesium per day) for 6 weeks
Number of subjects: 126
Study 28654669 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment) for 6 weeks
Number of subjects: 126
Study 26806542 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Hz mobilisation
Number of subjects: 60
Study 26806542 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz mobilisation
Number of subjects: 60
Study 26806542 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (sustained static pressure to L4 vertebra)
Number of subjects: 60
Study 26806542 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contact)
Number of subjects: 60
Study 25088287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime bipolar disorders and atypical depression
Number of subjects: 3719
Study 25088287 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use disorders (SUD) in men
Number of subjects: 3719
Study 25088287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime combined depression
Number of subjects: 3719
Study 25088287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime unspecified depression
Number of subjects: 3719
Study 25088287 — intervention group
Group type: EXPERIMENTAL
Intervention: Current combined depression
Number of subjects: 3719
Study 25088287 — intervention group
Group type: EXPERIMENTAL
Intervention: Current unspecified depression
Number of subjects: 3719
Study 21847611 — intervention group
Group type: EXPERIMENTAL
Intervention: High-low: 3.2 g BA/day for 4 weeks, followed by 1.6 g BA/day for 4 weeks
Number of subjects: 31
Study 21847611 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-low: 1.6 g BA/day for 8 weeks
Number of subjects: 31
Study 21847611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 19684100 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal home visit on day one
Number of subjects: 9211
Study 19684100 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal home visit on day two
Number of subjects: 9211
Study 19684100 — intervention group
Group type: COMPARATOR
Intervention: Postnatal home visit after day two
Number of subjects: 9211
Study 19589793 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFCA) of atrial fibrillation
Number of subjects: 56
Study 19589793 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiology study (EPS)
Number of subjects: 56
Study 15629816 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean angle width
Number of subjects: 275
Study 15629816 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock hours of PAS
Number of subjects: 275
Study 15629816 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated IOP
Number of subjects: 275
Study 15629816 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical cup-to-disc ratio
Number of subjects: 275
Study 15629816 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline untreated IOP
Number of subjects: 275
Study 12133155 — intervention group
Group type: COMPARATOR
Intervention: Attending physician only
Number of subjects: 134
Study 12133155 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending physician plus medical student
Number of subjects: 134
Study 10372875 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.0 mm lens
Number of subjects: 23
Study 10372875 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mm lens
Number of subjects: 23
Study 10372875 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.0 mm lens
Number of subjects: 23
Study 10372875 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.5 mm lens
Number of subjects: 23
Study 10372875 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 12.0 mm and 13.5 mm lenses
Number of subjects: 23
Study 10372875 — intervention group
Group type: COMPARATOR
Intervention: Comparison of lens diameter and comfort
Number of subjects: 23
Study 7547157 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide oxide 1 mg
Number of subjects: 0
Study 7547157 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide oxide 2 mg
Number of subjects: 0
Study 7547157 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 2 mg
Number of subjects: 0
Study 7547157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2206069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (up to 3 gm/hr)
Number of subjects: 156
Study 2206069 — intervention group
Group type: COMPARATOR
Intervention: No tocolytic therapy (control)
Number of subjects: 156
Study 6767944 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (3 x 200 mg/day)
Number of subjects: 25
Study 6767944 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 6767944 — intervention group
Group type: EXPERIMENTAL
Intervention: discontinuation of bezafibrate
Number of subjects: 25
Study 31928611 — intervention group
Group type: COMPARATOR
Intervention: Conventional with best-practice prevention (local anaesthetic, carious tissue removal, filling placement)
Number of subjects: 1144
Study 31928611 — intervention group
Group type: COMPARATOR
Intervention: Biological with best-practice prevention (sealing-in decay, selective carious tissue removal and fissure sealants)
Number of subjects: 1144
Study 31928611 — intervention group
Group type: COMPARATOR
Intervention: Best-practice prevention alone (dietary and toothbrushing advice, topical fluoride and fissure sealing of permanent teeth)
Number of subjects: 1144
Study 31928611 — intervention group
Group type: COMPARATOR
Intervention: Biological arm vs Conventional arm
Number of subjects: 1144
Study 31928611 — intervention group
Group type: COMPARATOR
Intervention: Prevention alone arm vs Conventional arm
Number of subjects: 1144
Study 28922935 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit stereotype threat (ST) priming
Number of subjects: 43
Study 28922935 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to high levels of trait perseveration
Number of subjects: 43
Study 28922935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ST priming)
Number of subjects: 43
Study 28003500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical management of risk factors
Number of subjects: 227
Study 28003500 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical activity levels
Number of subjects: 227
Study 28003500 — intervention group
Group type: COMPARATOR
Intervention: Out of target for systolic blood pressure and physical activity, higher mean low-density lipoprotein cholesterol and non-high-density lipoprotein
Number of subjects: 227
Study 24566991 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-week supervised aerobic and resistance training plus exercise counseling (EXE)
Number of subjects: 606
Study 24566991 — intervention group
Group type: COMPARATOR
Intervention: Counseling alone (CON)
Number of subjects: 606
Study 22657950 — intervention group
Group type: EXPERIMENTAL
Intervention: AXOS-enriched breads (2.2 g AXOS)
Number of subjects: 40
Study 22657950 — intervention group
Group type: COMPARATOR
Intervention: Control breads (non-endoxylanase treated)
Number of subjects: 40
Study 22657950 — intervention group
Group type: COMPARATOR
Intervention: Placebo breads
Number of subjects: 40
Study 22657950 — intervention group
Group type: EXPERIMENTAL
Intervention: AXOS-enriched breads
Number of subjects: 40
Study 19947803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (57 patients)
Number of subjects: 104
Study 19947803 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (47 patients)
Number of subjects: 104
Study 17697451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (100 microg/kg or a fixed dose of 6 mg)
Number of subjects: 617
Study 17697451 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (5 microg/kg/day)
Number of subjects: 617
Study 17697451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 617
Study 15103534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) delivered by trained social workers
Number of subjects: 52
Study 15103534 — intervention group
Group type: COMPARATOR
Intervention: Routine care from social workers (Control)
Number of subjects: 52
Study 11153777 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-guided management (n=49; 12 PTCA, 14 CABG, 23 drug therapy)
Number of subjects: 103
Study 11153777 — intervention group
Group type: COMPARATOR
Intervention: SPECT-guided management (n=54; 15 PTCA, 13 CABG, 26 drug therapy)
Number of subjects: 103
Study 9663912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril treatment after 3 and 12 months
Number of subjects: 170
Study 9663912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril plus hydrochlorothiazide treatment after 3 and 12 months
Number of subjects: 170
Study 9663912 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment after a final 4-week period
Number of subjects: 170
Study 7811826 — intervention group
Group type: COMPARATOR
Intervention: Lactulose hydrogen breath test
Number of subjects: 61
Study 2839321 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose 4 g
Number of subjects: 109
Study 2839321 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose 1 g, 2 g, or 4 g
Number of subjects: 109
Study 2839321 — intervention group
Group type: COMPARATOR
Intervention: Psyllium 3.4 g
Number of subjects: 109
Study 16303008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus (SRL) with low-dose MMF
Number of subjects: 21
Study 16303008 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cyclosporine (CsA) with low-dose MMF
Number of subjects: 21
Study 31284842 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP services offered at FQHCs
Number of subjects: 360